By Colin Kellaher


Bayer AG on Tuesday said the U.S. Food and Drug Administration granted priority review to finerenone for patients with chronic kidney disease and type 2 diabetes.

The Leverkusen, Germany, chemical and pharmaceutical company said finerenone offers a potential new strategy to delay the progression of chronic kidney disease in people with type 2 diabetes while reducing the risk of cardiovascular events.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period to six months from the standard 10 months.

Bayer said there is currently a significant unmet medical need for the nearly 40% of people in the U.S. with type 2 diabetes who will develop chronic kidney disease, a progressive condition can lead to kidney damage and eventual failure.


Write to Colin Kellaher at


(END) Dow Jones Newswires

January 12, 2021 09:05 ET (14:05 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (XE:BAYN)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Bayer Charts.
Bayer (XE:BAYN)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Bayer Charts.